Phase 3 Study Shows BI Bevacizumab Biosimilar Comparable to Reference Product

January 19, 2022

Two biosimilars, Pfizer’s Zirabev and Amgen’s Mvasi, have been approved for indications including unresectable, locally advanced NSCLC and recurrent or metastatic nonsquamous NSCLC. BI 695502 is no longer under development by Boehringer Ingelheim.

Industry Group Representative Discusses Biosimilars in Michigan
Real-world Study Sees Adoption of Mvasi by US Oncologists for Metastatic CRC
Pharmacokinetic and Pharmacodynamic Equivalence of Biocon’s Proposed Biosimilar Insulin-R to Humulin-R
Wayne Winegarden, PhD, Discusses Which Insurance Type He Expects Will Have the Greatest Biosimilar Savings